Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

987 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.
Li Q, Chitnis A, Hammer M, Langer J. Li Q, et al. Among authors: langer j. Diabetes Ther. 2014 Dec;5(2):579-90. doi: 10.1007/s13300-014-0084-9. Epub 2014 Sep 26. Diabetes Ther. 2014. PMID: 25256818 Free PMC article.
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC, Samyshkin Y, Langer J, Palmer JL. Lee WC, et al. Among authors: langer j. J Med Econ. 2012;15 Suppl 2:28-37. doi: 10.3111/13696998.2012.716111. Epub 2012 Aug 13. J Med Econ. 2012. PMID: 22834986
Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
Malmenäs M, Bouchard JR, Langer J. Malmenäs M, et al. Among authors: langer j. Clin Ther. 2013 Jun;35(6):795-807. doi: 10.1016/j.clinthera.2013.03.021. Epub 2013 May 1. Clin Ther. 2013. PMID: 23642290
Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. DeKoven M, et al. Among authors: langer j. Adv Ther. 2014 Feb;31(2):202-16. doi: 10.1007/s12325-014-0098-8. Epub 2014 Jan 30. Adv Ther. 2014. PMID: 24477354 Free PMC article.
Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.
Lee WC, Dekoven M, Bouchard J, Massoudi M, Langer J. Lee WC, et al. Among authors: langer j. Diabetes Obes Metab. 2014 Sep;16(9):819-26. doi: 10.1111/dom.12285. Epub 2014 Mar 25. Diabetes Obes Metab. 2014. PMID: 24581276
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Chitnis AS, et al. Among authors: langer j. Adv Ther. 2014 Sep;31(9):986-99. doi: 10.1007/s12325-014-0153-5. Epub 2014 Sep 23. Adv Ther. 2014. PMID: 25245811 Free PMC article.
Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
Buysman EK, Liu F, Hammer M, Langer J. Buysman EK, et al. Among authors: langer j. Adv Ther. 2015 Apr;32(4):341-55. doi: 10.1007/s12325-015-0199-z. Epub 2015 Apr 2. Adv Ther. 2015. PMID: 25832470 Free PMC article.
Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
Lorenzi M, Ploug UJ, Langer J, Skovgaard R, Zoratti M, Jansen J. Lorenzi M, et al. Among authors: langer j. Diabetes Ther. 2017 Feb;8(1):85-99. doi: 10.1007/s13300-016-0217-4. Epub 2016 Dec 19. Diabetes Ther. 2017. PMID: 27995594 Free PMC article.
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.
Hunt B, Mocarski M, Valentine WJ, Langer J. Hunt B, et al. Among authors: langer j. Diabetes Ther. 2017 Jun;8(3):531-544. doi: 10.1007/s13300-017-0251-x. Epub 2017 Mar 27. Diabetes Ther. 2017. PMID: 28349444 Free PMC article.
A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
Webb N, Orme M, Witkowski M, Nakanishi R, Langer J. Webb N, et al. Among authors: langer j. Diabetes Ther. 2018 Jun;9(3):973-986. doi: 10.1007/s13300-018-0397-1. Epub 2018 Mar 24. Diabetes Ther. 2018. PMID: 29574633 Free PMC article.
987 results
Jump to page
Feedback